Although combinations of anti-HIV drugs can effectively suppress virus replication, infected individuals possess a reservoir of latent HIV-1. Upon cessation of drugs, viruses in this reservoir reactivate and re-kindle infection, thereby preventing a cure of infectio. To purge the viral reservoir, a strategy termed "shock-and-kill" has been described. This strategy proposes to develop small molecules that reactivate latent HIV without inducing global T cell activation. A recent study has shown that a histone deacetylase inhibitor (HDACi) known as vorinostat (also named SAHA) can reactivate latent HIV in some patients, providing evidence that the shock-and-kill strategy may be feasible. In addition to its ability to derepress the chromatin state of the integrated HIV provirus, our recent results demonstrate that vorinostat can stimulate P-TEFb in resting primary CD4+ T cells through activation of CDK9 Thr186 (T-loop) phosphorylation. P-TEFb is a cellular cofactor whose core is composed of CDK9 and Cyclin T1 and it mediates HIV Tat activation of the integrated provirus. Phosphorylation of the CDK9 T-loop is essential for its kinase function and is therefore also essential for Tat function. In resting CD4+ T cells, however, CDK9 T-loop phosphorylation is repressed. Therefore, activation of CDK9 T-loop phosphorylation by vorinostat likely contributes to its ability to reactivate latent virus in patients. We propose to investigate mechanisms by which vorinostat and other HDACis activate CDK9 T-loop phosphorylation in resting CD4+ T cells. Given that vorinostat is currently being evaluated in human trials for the ability to reactivate latent HIV, i is important to understand its mechanisms of action. The proposed research can aid in the development of more potent reactivating molecules, as well as inform clinical protocols that utilize the shock-and-kill strategy. The research proposed in this application has the potential fo a high impact on strategies to cure HIV infection.

Public Health Relevance

We will identify mechanisms involved in the reactivation of latent HIV-1 by small molecules. Identification of these mechanisms may enable development of new and more potent drugs to reactivate latent HIV-1, and this may contribute to strategies to cure infection.

Agency
National Institute of Health (NIH)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI110263-01A1
Application #
8786930
Study Section
AIDS Discovery and Development of Therapeutics Study Section (ADDT)
Program Officer
Lawrence, Diane M
Project Start
Project End
Budget Start
Budget End
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Baylor College of Medicine
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77030